Date | Time | Source | Headline | Symbol | Company |
05/07/2024 | 7:00AM | GlobeNewswire Inc. | Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update | NYSE:NVS | Novartis AG |
04/23/2024 | 7:25AM | IH Market News | Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News | NYSE:NVS | Novartis AG |
04/15/2024 | 2:00PM | PR Newswire (US) | New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) | NYSE:NVS | Novartis AG |
04/11/2024 | 7:00AM | GlobeNewswire Inc. | Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer | NYSE:NVS | Novartis AG |
04/10/2024 | 7:13AM | IH Market News | Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News | NYSE:NVS | Novartis AG |
04/06/2024 | 4:16PM | PR Newswire (US) | New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting | NYSE:NVS | Novartis AG |
02/15/2024 | 4:15PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NYSE:NVS | Novartis AG |
02/06/2024 | 4:52PM | Edgar (US Regulatory) | Form SC TO-C - Written communication relating to an issuer or third party | NYSE:NVS | Novartis AG |
02/06/2024 | 6:14AM | IH Market News | Boeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and More | NYSE:NVS | Novartis AG |
02/05/2024 | 5:06PM | Edgar (US Regulatory) | Form SC TO-C - Written communication relating to an issuer or third party | NYSE:NVS | Novartis AG |
02/02/2024 | 2:18PM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NYSE:NVS | Novartis AG |
01/31/2024 | 7:44AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:NVS | Novartis AG |
01/31/2024 | 7:43AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:NVS | Novartis AG |
01/31/2024 | 7:42AM | Edgar (US Regulatory) | Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)). | NYSE:NVS | Novartis AG |
01/31/2024 | 7:38AM | Edgar (US Regulatory) | Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | NYSE:NVS | Novartis AG |
01/31/2024 | 6:28AM | IH Market News | Walmart’s Stock Split, Elon Musk’s Billion-Dollar Package Revoked, and More | NYSE:NVS | Novartis AG |
01/22/2024 | 1:59AM | Dow Jones News | Sandoz to Acquire Cimerli Business from Coherus for $170 Million | NYSE:NVS | Novartis AG |
01/12/2024 | 6:10AM | IH Market News | Wall Street Highlights: DocuSign Acquisition Battle, Tesla Berlin Production Halt, and More | NYSE:NVS | Novartis AG |
01/11/2024 | 1:02PM | Dow Jones News | Cytokinetics Shares Slide as Novartis Reportedly Shies Away From Deal | NYSE:NVS | Novartis AG |
01/08/2024 | 1:43PM | Dow Jones News | Cytokinetics Shares Jump 16% After WSJ Report of Novartis Deal | NYSE:NVS | Novartis AG |
01/08/2024 | 10:41AM | Dow Jones News | Novartis on Track for Record High Close -- Data Talk | NYSE:NVS | Novartis AG |
01/08/2024 | 6:13AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:NVS | Novartis AG |
01/08/2024 | 2:01AM | Dow Jones News | Novartis's Scemblix Drug Meets Main Goals in Late-Stage Leukemia Trial | NYSE:NVS | Novartis AG |
01/05/2024 | 10:15AM | Dow Jones News | Novartis to Make Pluvicto Radioligand Therapy at Indianapolis Plant | NYSE:NVS | Novartis AG |
01/02/2024 | 7:46AM | Dow Jones News | Voyager Therapeutics Shares Leap Premarket on Novartis Collaboration | NYSE:NVS | Novartis AG |
12/11/2023 | 6:05AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NYSE:NVS | Novartis AG |
12/11/2023 | 2:02AM | Dow Jones News | Novartis Drug Meets Primary Goal in Late-Stage Study for Kidney Disease | NYSE:NVS | Novartis AG |
12/10/2023 | 7:39PM | PR Newswire (US) | Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) | NYSE:NVS | Novartis AG |
12/06/2023 | 5:14AM | Dow Jones News | Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials | NYSE:NVS | Novartis AG |
12/06/2023 | 12:18AM | PR Newswire (US) | Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH | NYSE:NVS | Novartis AG |